Early predictions of response and survival from a tumor dynamics model in patients with recurrent, metastatic head and neck squamous cell carcinoma treated with immunotherapy
Abstract We developed and evaluated a method for making early predictions of best overall response (BOR) and overall survival at 6 months (OS6) in patients with cancer treated with immunotherapy. This method combines machine learning with modeling of longitudinal tumor size data. We applied our meth...
Main Authors: | Ignacio González‐García, Vadryn Pierre, Vincent F. S. Dubois, Nassim Morsli, Stuart Spencer, Paul G. Baverel, Helen Moore |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-03-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.12594 |
Similar Items
-
Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
by: Ronan W. Hsieh, et al.
Published: (2021-09-01) -
Current trends in the immunotherapy of metastatic and recurrent squamous cell carcinoma of the head and neck
by: Yu. V. Kostalanova, et al.
Published: (2020-11-01) -
Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
by: Christian Borel, et al.
Published: (2020-09-01) -
Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma
by: Rosalinda Arends, et al.
Published: (2021-01-01) -
Challenges in Combining Immunotherapy with Radiotherapy in Recurrent/Metastatic Head and Neck Cancer
by: Gaber Plavc, et al.
Published: (2020-10-01)